MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ
4.770
+0.010
+0.21%
After Hours: 4.790 +0.02 +0.42% 16:56 05/01 EDT
OPEN
4.760
PREV CLOSE
4.760
HIGH
4.900
LOW
4.620
VOLUME
1.75M
TURNOVER
0
52 WEEK HIGH
7.00
52 WEEK LOW
3.295
MARKET CAP
277.60M
P/E (TTM)
109.40
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VNDA last week (0422-0426)?
Weekly Report · 2d ago
UPDATE 1-Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer of $7.75 per share in cash. Last week, Vanda rejected contract manufacturer's offer for 59%-70% premium to Wednesday's closing price. Vanda said it rejected the offer because it significantly undervalued company.
Reuters · 6d ago
Vanda Pharmaceuticals Shareholder ShareCap Says Company Board Must Explore Strategic Alternatives
Benzinga · 6d ago
SHAREHOLDER CAPITAL LLC : CALLS VANDA PHARMACEUTICALS' BOARD TO RECONSIDER FUTURE PAK'S OFFER
Reuters · 6d ago
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 04/24 17:58
Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex
NASDAQ · 04/23 01:06
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
The U.S. Supreme Court has reportedly declined to review Vanda Pharmaceuticals Inc’s attempt to revive patents for its sleep-disorder medication Hetlioz. Vanda had previously had its patents invalidated in a legal battle with generic drugmakers Teva Pharmaceutical Industries.
Benzinga · 04/22 18:37
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 04/22 18:10
More
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.